Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 9, 2015, Pages 1039-1044

  Bliven Sizemore, E E ^a   Sterling, T R ^b   Shang, N ^a   Benator, D ^c   Schwartzman, K ^d   Reves, R ^e   Drobeniuc, J ^f   Bock, N ^a   Villarino, M E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF COLORADO   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Aspartate aminotransferases; Hepatitis C; Isoniazid

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ISONIAZID; RIFAPENTINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CASE CONTROL STUDY; CAUCASIAN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; LATENT TUBERCULOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RISK ASSESSMENT; RISK FACTOR; SEX; SIDE EFFECT; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; BRAZIL; CANADA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; SPAIN; TOXIC HEPATITIS; UNITED STATES;

ADULT; ANTITUBERCULAR AGENTS; ASPARTATE AMINOTRANSFERASES; BRAZIL; CANADA; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS C; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RIFAMPIN; RISK FACTORS; SPAIN; UNITED STATES;

EID: 84973420312     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0829     Document Type: Article

References (18)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M C. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-686.
2. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 (4 Pt 2): S221-S247.
3. Institute of Medicine. Ending neglect: The elimination of tuberculosis in the United States. Washington DC, USA: National Academy of Sciences, 2000.
4. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO, 2011. http://whqlibdocwhoint/publications/2011/9789241500708-engpdf. Accessed June 2015.
5. Sterling T R, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh C R. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006; 173: 927-931.
6. Saukkonen J J, Cohn D L, Jasmer R M et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
7. Bliven E E, Podewils L J. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. Int J Tuberc Lung Dis 2009; 13: 1054-1060.
8. Sterling T R, Villarino ME, Borisov A S, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
9. Cancer Therapy Evaluation Program. The revised common toxicity criteria: version 2.0. Bethesda, MD, USA: CTEP, 1999. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcmanual-v4-10-4-99.pdf. Access June 2015.
10. Ewing J A. Detecting alcoholism. The CAGE questionnaire. JAMA 1984; 252: 1905-1907.
11. Nolan CM, Goldberg S V, Buskin S E. Hepatoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
12. Kopanoff D E, Snider D E Jr, Caras G J. Isoniazid-related hepatitis: A US Public Health Service Cooperative Surveillance Study. Am Rev Respir Dis 1978; 117: 991-1001.
13. Snider D E Jr, Caras G J. Isoniazid-associated hepatitis deaths: A review of available information. Am Rev Respir Dis 1992; 145: 494-497.
14. Moulding T. Toxicity associated with isoniazid preventative therapy. JAMA 1999; 282: 2207.
15. Sadaphal P, Astemborski J, Graham N M, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001; 33: 1687-1691.
16. Fernandez-Villar A, Sopena B, Vazquez R, et al. Isoniazid hepatotoxicity among drug users: The role of hepatitis C. Clin Infect Dis 2003; 36: 293-298.
17. Pettit A C, Bethel J, Hirsch-Moverman Y, Colson P W, Sterling T R. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect 2013; 67: 424-432.
18. Martinson N A, Barnes G L, Moulton L H, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365: 11-20.